开放合作的资产

Hu-VHH抗体资产

单个VHH结构域（约12-15 kDa）具有更优的实体瘤和血脑屏障穿透能力，是具有广阔前景的诊断和治疗工具。
  • 200+
    Hu-VHH 项目
  • 200+
    全人抗体合作项目
获取数据包 预定会议
相关资源

在此页面上

  • 探索百奥赛图的Hu-VHH在多特异性抗体、ADC和细胞治疗中的新机会
  • 百奥赛图的RenNano小鼠：全人仅重链抗体平台，用于VHH发现
  • RenNano平台相关抗体库
  • FAQs

网络研讨会

查看全部

    海报

    查看全部

      探索百奥赛图的Hu-VHH在多特异性抗体、ADC和细胞治疗中的新机会

      单个VHH结构域（约12-15 kDa）因其更优的实体瘤和血脑屏障穿透能力，展现出广阔的诊断和治疗应用前景。

      The single VHH domain (~12-15 kDa) img

      百奥赛图的RenNano小鼠：全人仅重链抗体平台，用于VHH发现

      RenNano小鼠是通过对RenMab小鼠抗体恒定区进行基因改造而开发的。免疫后，RenNano小鼠能够产生全人源重链抗体（HCAbs），这种抗体无需轻链即可结合抗原。RenNano来源的HCAbs具有多样化的CDR3序列，能够以优异的特异性和亲和力识别多种表位。RenNano小鼠产生的HCAbs在体内外均表现出强大的生物学功能，适用于多种药物形式，包括双特异性抗体、多特异性抗体、抗体药物偶联物（ADC）及细胞疗法。

      Biocytogen's RenNano Mice img Biocytogen's RenNano Mice img 2

      RenNano平台相关抗体库

      Target Dev Stage Species cross-reactivity Internalization Assay Affinity
      CD71 Leads Selection √ √ √
      CD98 Leads Selection √ √ √
      MUC16 Leads Selection √ √ √
      PSMA Leads Selection √ √ √
      MET Leads Selection √ √ √
      4-1BB Leads Selection √ NA √
      VEGFA Leads Selection √ NA √
      ALB Leads Selection √ NA √
      RSV Leads Selection NA NA √
      DLL3 Leads Selection √ √ √
      CD28 Leads Selection √ NA √
      CD3e Leads Selection √ NA √
      EGFR Leads Selection √ √ √
      PD-L1 Hits Selection √ NA √
      TNFR2 Hits Selection √ NA √
      CD38 Hits Selection √ NA √
      GPRC5D Hits Selection √ √ √
      HER3 Hits Selection √ √ √
      GUCY2C Hits Selection √ √ √
      IL6ST Hits Selection √ NA √
      IL6R Hits Selection √ NA √
      ADAM9 Hits Selection √ NA √
      FAP Hits Selection √ √ √
      PTK7 Hits Selection √ √ √
      TPBG Hits Selection √ In progress In progress
      IL3RA Hits Selection √ NA √
      MSLN Hits Selection √ √ √
      TSLP Hits Selection √ NA In progress
      OX40 Hits Selection √ NA √
      TROP2 Hits Selection √ √ √
      Nectin-4 Hits Selection √ √ √
      ROR1 Hits Selection √ √ √
      CD22 Hits Selection √ NA √
      FOLR1 Hits Selection √ √ √
      IL13RA2 Hits Selection √ NA √
      TFR1-TOP HCAbs

      CD71，也称为TFR1（转铁蛋白受体1），是一种单跨膜蛋白，主要通过与转铁蛋白（Transferrin, TF）结合将铁离子运输入细胞。抗TFR1抗体被广泛用作穿越血脑屏障（BBB）的递送载体。

      TFR1-TOP抗体在体内表现出更好的BBB渗透能力和优势

      • 比基准抗体具有更好的BBB渗透能力
      • 单价形式比双价形式具有更好的BBB渗透性
      • 可灵活应用于非偶联型递送（如融合蛋白或双特异性抗体）或偶联型药物递送（如抗体-寡核苷酸偶联物AOC或小分子药物）
      比基准抗体具有更好的BBB渗透能力
      Better BBB penetrance than Benchmark
      单价vs.双价
      Monovalent vs. Bivalent

      百奥赛图正在积极寻求与全球制药及生物技术公司的合作，聚焦VHH相关治疗领域，包括细胞疗法、血脑屏障穿越系统（BBB shuttle）、双特异性及多特异性抗体、抗体药物偶联物（ADC）以及受体抗体偶联物（RAC）等，旨在共同开发具有“同类首创”或“同类最优”潜力的新型药物。

      了解共同开发或许可事宜，请随时联系我们！

      Frequently Asked Questions (FAQs) About Hu-VHH Assets

      1. What characterization data are available for Biocytogen’s Hu-VHH antibody assets?

      Available characterization data package typically include binding affinity, species cross-reactivity, internalization, and developability assessments, depending on the individual asset. These data help partners evaluate and select candidates aligned with their therapeutic applications and development requirements.

      2. How can Hu-VHH/HCAb binders support BBB shuttle and AOC applications?

      Biocytogen’s TFR1- and CD98-targeting HCAb/VHH binders can serve as BBB shuttles for brain delivery applications. VHH/HCAb formats can also be adapted for antibody-oligonucleotide conjugate (AOC), with site-specific antibody modification enabling controlled oligonucleotide attachment required for AOC development.

      3. What collaboration options are available for Biocytogen’s Hu-VHH assets?

      Biocytogen’s Hu-VHH assets are available for evaluation, licensing, and co-development. Partners can request data packages for selected assets or schedule a meeting with our team to discuss candidate evaluation and an appropriate collaboration model.

      4. How to access Biocytogen’s hu-VHH/HCAb library?

      Partners can explore Biocytogen’s RenNano®-derived fully human VHH and HCAb library through RenSuper™ Workstation at rensuperbio.com. The library spans over 1,000 targets with sequences available or discovery underway, covering oncology, autoimmune diseases, neurological diseases and more.
      Available targets, clones, and preliminary data are updated regularly. Partners can search for binders of interest or contact Biocytogen to confirm availability, request supporting data, and discuss collaboration.